ICMJE DISCLOSURE FORM

| Date | e: 22. januar 2025 | | |
|--------------------------|--|---|---|
| You | r name: Agnes Nannerup |) | |
| | nuscript title: Intrave | | effective steroid-sparring drug in inflammatory |
| | nuscript number (if known): | | |
| | | | |
| are re third comn | elated to the content of yo parties whose interests ma | ur manuscript. "Related" ay be affected by the cont nd does not necessarily in | relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so. |
| | following questions apply to uscript only. | o the author's relationship | os/activities/interests as they relate to the <u>current</u> |
| perta antih In ite | nins to the epidemiology of ypertensive medication, ev | hypertension, you should yen if that medication is n port for the work reported | defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript. d in this manuscript without time limit. For all months. |
| | | | |
| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
| Time | e frame: Since the initial plan | ning of the work | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | None | |
| | No time limit for this | | |
| | item. | | |
| | | | Click TAB in last row to add extra rows |
| Time | e frame: past 36 months | | |
| 2 | Cranto or contracts for a | M None | - |
| 2 | Grants or contracts from any entity (if not indicated | None Non | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | | |
| | nogarios or noonsos | EN MONIC | |
| | | | |

| 4 | Consulting fees | ⊠ None |
|----|---|-----------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None None |
| 6 | Payment for expert testimony | None |
| 7 | Support for attending meetings and/or travel | None |
| 8 | Patents planned, issued or pending | ⊠ None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None None |
| 11 | Stock or stock options | None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None |
| 13 | Other financial or non- financial interests | None |

Please place an "X" next to the following statement to indicate your agreement:

 \boxtimes I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

ICMJE DISCLOSURE FORM

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

| Date: 22. januar 2025 | | | |
|--|--|--|--|
| Your name: Esben U. Næser | | | |
| Manuscript title: Intravenous immune globulin is an effective steroid-sparring drug in inflammatory myositis | | | |
| Manuscript number (if known): | | | |
| | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----|---|--|---|
| Tim | Time frame: Since the initial planning of the work | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | ⊠ None | |
| | No time limit for this item. | | |

Click TAB in last row to add extra rows

| Time frame: past 36 months | | | | |
|----------------------------|------------------------------|-----------------------|---|--|
| | | | | |
| 2 | Grants or contracts from | □ None | | |
| | any entity (if not indicated | Independent Research | Research grant for research year student, payment | |
| | in item #1 above). | Fund Denmark | to Aarhus University | |
| | | The Danish Rheumatism | Research grant, payment to Aarhus University | |
| | | Association | Hospital | |
| | | | | |
| 3 | Royalties or licenses | None | | |
| | | | | |
| | | | | |

| 4 | Consulting fees | ⊠ None | |
|----|---|---|-----------------------------|
| | | | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ■ None Boehringer Ingelheim GmbH GlaxoSmithKline | Educational event Lectures |
| 6 | Payment for expert testimony | None Non | |
| 7 | Support for attending meetings and/or travel | ⊠ None | |
| 8 | Patents planned, issued or pending | ⊠ None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None Non | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None Non | |
| 11 | Stock or stock options | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ⊠ None | |
| 13 | Other financial or non- financial interests | None Non | |

Please place an "X" next to the following statement to indicate your agreement:

 \boxtimes I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

| Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal. |
|--|
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |

ICMJE DISCLOSURE FORM

| Date | e : 21. januar 2025 | | |
|-------------------------|--|---|---|
| You | r name: Lars Erik Bartels | 8 | |
| | | enous immune globulin is an | effective steroid-sparring drug in inflammatory |
| | nuscript number (if known) | | |
| are re third comr | elated to the content of you parties whose interests ma | ur manuscript. "Related" ay be affected by the cont nd does not necessarily in | relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so. |
| | ollowing questions apply to uscript only. | o the author's relationship | os/activities/interests as they relate to the <u>current</u> |
| perta antih | ins to the epidemiology of ypertensive medication, ev | hypertension, you should yen if that medication is n | defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript. |
| | m#1 below, report all supprited in the firms, the time frame for | • | d in this manuscript without time limit. For all months. |
| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
| Time | e frame: Since the initial plan | - | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | ⊠ None | |
| | No time limit for this item. | | |
| | | | Click TAB in last row to add extra rows |
| Time | e frame: past 36 months | | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |
| 3 | Royalties or licenses | None Non | |
| | | | |
| | | | |

| 4 | Consulting fees | ⊠ None |
|----|---|-----------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None None |
| 6 | Payment for expert testimony | None |
| 7 | Support for attending meetings and/or travel | None |
| 8 | Patents planned, issued or pending | ⊠ None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None None |
| 11 | Stock or stock options | None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None |
| 13 | Other financial or non- financial interests | None |

Please place an "X" next to the following statement to indicate your agreement:

 \boxtimes I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal